Clinical Trials Logo

Clinical Trial Summary

Renal parenchymal blood flow can be divided in cortical and medullary blood flow. Changes and factors affecting renal medullary blood flow have not been studied in detail previously as investigators/doctors did not have tools to monitor renal medullary blood flow in vivo. Since Trueta first described renal medullary blood flow, multiple attempts have been made to study renal medullary blood flow using invasive methods. Recently renal medullary blood flow measurement using contrast US has emerged as a promising technique that investigators can use to study renal medullary blood flow in vivo. In this study investigators are aiming to study changes in renal parenchymal (cortical and medullary) blood flow with exercise in healthy subject.


Clinical Trial Description

This study requires a screening day and two visits on separate days to the Clinical Research Unit (CRU). Three visits total.

Screening Visit:

1. The subjects will undergo detailed history and physical examination.

2. The inclusion and exclusion criteria will be reviewed.

3. The details of the study procedures, potential risks and benefits will be reviewed with each subject and all potential questions will be answered.

4. Subjects' understating of all details of the study components will be ascertained and they will be asked to sign the informed consent form.

5. A copy of the signed informed consent will be placed in study file and another copy will be provided to each subject.

6. The study visit day will be scheduled within 2 weeks of the screening day.

7. All subjects will be asked to arrive on their first study day after an overnight fast. They will be instructed to avoid caffeine and exercise for 24 hours.

Study Day #1 The subjects will arrive in the CRU in the morning. Subjects' understanding of all study related procedures will be assessed and all remaining questions will be answered. The following sequence of procedures will be followed for all enrolled subjects.

1. Physical exam including vital signs (Blood Pressure, Heart Rate, Weight, Height, Respiration Rate, Temperature)

2. Urine pregnancy test for women of child bearing age. If positive, subjects will be excluded.

Determination of peak oxygen consumption

3. Subjects will complete a continuous VO2 peak bicycle ergometer protocol.

1. Each subject will start peddling on a stationary bike

2. The initial power output (PO) will be set at 20 watts

3. The power output will be increased by 15 watts every 2-minutes until volitional exhaustion.

4. Metabolic data will be collected during the protocol using standard open-circuit spirometric techniques (Viasys Vmax Encore, Yorba Linda, CA)

5. Heart rate was assessed electrocardiographically.

6. VO2 peak will be chosen as the highest VO2 attained during the exercise protocol

On Day 2 of testing

1. Check Vitals (BP, HR, Wt., RR, Temp.)

2. Insert peripheral IV line Baseline renal blood flow measurement using contrast enhanced ultrasonography

3. The Definity vial will be placed at room temperature before being used. It will be activated after shaking the vial using Vialmax® for 45 seconds. It will be used immediately after activation.

4. 0.4 ml of Definity will be mixed in 10 ml of preservative free saline.

5. Infusion of Definity into a peripheral vein will be started at 2 ml/min and titrated for optimal image quality using a minipump (not to exceed 10 ml/min at any time).

6. Baseline contrast ultrasound imaging of right kidney will be performed with low mechanical index (MI) of 0.2.

7. 4 - 5 ultrasound impulses with high MI of 1.0 and duration of 1 second will be used to destruct the microbubbles in the kidney tissue

8. Ultrasound imaging of the kidney with low MI (0.2) will continue immediately after each impulse for several seconds.

9. Infusion of Definity will stop at this point.

10. Vital signs will be monitored every 15 minutes and continuous pulse oximetry will be performed during Definity administration.

11. Vital signs and pulse oximetry will be monitored every 15 minutes until 30 minutes after discontinuation of Definity.

12. A urine dipstick will be performed by the study team 30 minutes after completion of Definity infusion if a sample is available.

Constant load Exercise protocol

13. Subjects will complete 30 minutes of continuous cycling at the power output associated with 85% of VO2peak from the continuous bicycle ergometer protocol. Metabolic data will be collected as described above.

14. Once metabolic parameter are reached, exercise will be stopped and subject will be asked to lie down on the bed Renal Blood flow measurement following exercise using contrast enhanced ultrasonography

15. Immediately after completion of exercise protocol, steps 5 - 12 under day 2 procedures will be repeated.

16. The study procedures will end at this point. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02672722
Study type Interventional
Source University of Virginia
Contact Sharon F Johnson, BA
Phone 4349823198
Email sfj8n@virginia.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date January 2016
Completion date October 2017

See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1